Mon, October 7, 2024

Matt O"Brien Maintained (TMDX) at Buy and Held Target at $180 on, Oct 7th, 2024

Matt O"Brien of Piper Sandler, Maintained "TransMedics Group, Inc." (TMDX) at Buy and Held Target at $180 on, Oct 7th, 2024.

Matt has made no other calls on TMDX in the last 4 months.

There are 7 other peers that have a rating on TMDX. Out of the 7 peers that are also analyzing TMDX, 1 agrees with Matt"s Rating of Hold. Following is the relevant analyst calls for the last 4 months;

Patrick Wood of "Morgan Stanley" Maintained at Hold with Increased Target to $145 on, Monday, July 15th, 2024

These are the ratings of the 6 analyists that currently disagree with Matt;

Joe Vruwink of "Baird" Initiated at Buy and Held Target at $200 on, Tuesday, September 24th, 2024
Mike Matson of "Needham" Reiterated at Strong Buy and Held Target at $208 on, Friday, August 23rd, 2024
George Sellers of "Stephens & Co." Maintained at Buy with Increased Target to $178 on, Friday, August 2nd, 2024
Jason Mills of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $169 on, Thursday, August 1st, 2024
Suraj Kalia of "Oppenheimer" Maintained at Buy with Increased Target to $200 on, Thursday, August 1st, 2024
Joshua Jennings of "TD Cowen" Maintained at Strong Buy with Increased Target to $175 on, Friday, June 7th, 2024